Coya Therapeutics, Inc. COYA
3.21 USD +0.05 (+1.58%)
At closeNov 11, 2026, 4:00 PM EST
3.09 -0.12 -3.73%
After hours · Nov 11, 4:00 PM ET
3.17 Day range 3.31
2.72 52-week range 6.62
- YTD
- -44.66%
- 1 year
- -46.59%
News
benzinga.com Coya Therapeutics Q3 EPS $(0.45) Misses $(0.34) Estimate, Sales $234.134K Beat $85.714K Estimate Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.34) by 32.35 percent. This is a 246.15 percent decrease over losses…
businesswire.com Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…- benzinga.com Coya Therapeutics To Highlight ALS Data In Poster Presentation At 2026 Annual NEALS Meeting; Co. Currently Conducts ALSTARS Trial, Phase 2/3, Study To Evaluate COYA 302 For ALS Treatment ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individualsThe Company believes…
benzinga.com Coya Therapeutics Plans To Initiate Open-Label Extension Of Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Treatment Of Amyotrophic Lateral Sclerosis OLE planned in response to requests from ALSTARS investigators and participantsEligible participants completing 48 weeks of treatment will have the opportunity to continue receiving COYA 302Cash…